Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.86 |
| ▸ | CHAT | P28329 | 2/20 | 0.82 |
| ▸ | EP300 | Q09472 | 3/20 | 0.81 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.81 |
| ▸ | AURKA | O14965 | 2/20 | 0.81 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.81 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexanoyl-Coa SCHEMBL21496009 | 1.00 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| Hexanoyl-Coa SCHEMBL60392 | 1.00 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| Octanoyl-Coa SCHEMBL2370508 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL11027446 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL2934083 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| Decanoyl-Coa SCHEMBL24667667 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL1756475 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL20970006 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| Octanoyl-Coa SCHEMBL24667663 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL1129961 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340446-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | GINKGO BIOWORKS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340555-A1 | PRODUCTION OF GLYCOSYLATED CANNABINOIDS | WILLOW BIOSCIENCES, INC. (CA) | 2023-10-26 | — | — | US | disclosed |
| US-20230340506-A1 | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230279449-A1 | COMPOSITIONS AND METHODS FOR ENHANCING RECOMBINANT BIOSYNTHESIS OF CANNABINOIDS | WILLOW BIOSCIENCES, INC. (CA) | 2023-09-07 | — | — | US | disclosed |
| US-9970037-B2 | Methods and materials for making simvastatin and related compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170029790-A1 | VARIANT LovD POLYPEPTIDE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170022525-A1 | METHOD FOR PRODUCING METHACRYLIC ACID ESTER AND NOVEL METHACRYLIC ACID ESTER SYNTHETASE | MITSUBISHI RAYON CO., LTD. (JP) | 2017-01-26 | — | — | US | disclosed |
| US-9499803-B2 | Variant LovD polypeptide | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-22 | — | — | US | disclosed |
| US-9139694-B1 | High temperature materials with low moisture uptake made from lichen metabolites | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150218531-A1 | VARIANT LovD POLYPEPTIDE | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-08-06 | — | — | US | disclosed |
| US-20150203884-A1 | METHODS AND MATERIALS FOR MAKING SIMVASTATIN AND RELATED COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-07-23 | — | — | US | disclosed |
| US-8981056-B2 | Variant LovD polypeptide | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8951754-B2 | Methods and materials for making simvastatin and related compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-10 | — | — | US | disclosed |
| US-20120315680-A1 | METHODS AND MATERIALS FOR MAKING SIMVASTATIN AND RELATED COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120190038-A1 | LovD MUTANTS EXHIBITING IMPROVED PROPERTIES TOWARDS SIMVASTATIN SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029790-A1 | VARIANT LovD POLYPEPTIDE | FNTA, PCSK9, HMGCR | NAA50 2505/4885CHAT 4224/4885EP300 4595/4885 |
| US-20150218531-A1 | VARIANT LovD POLYPEPTIDE | FNTA, PCSK9, HMGCR | NAA50 2505/4885CHAT 4224/4885EP300 4595/4885 |
| US-20230340506-A1 | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | CNR2, CNR1, FAAH | NAA50 145/4885CHAT 222/4885EP300 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.